Clinical trial
A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive…
NCT00368030 · Sumitomo Pharma America, Inc., Industry · Completed
Key facts
| NCT number | NCT00368030 |
|---|---|
| Title | A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder |
| Official title | Depression Response to Eszopiclone in Adults With Major Depressive Disorder (DREAMDD): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 8-Week, Safety & Efficacy Study of Eszopiclone 3 mg Compared to Placebo in Subjects With Insomnia Related to MDD Acronym: DREAMDD |
| Lead sponsor | Sumitomo Pharma America, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Insomnia, Depressive Disorder, Major |
| Intervention type | Drug, Other |
| Interventions | Eszopiclone, Placebo |
| Enrollment | 545 |
| Start date | Jan 1, 2004 |
| Primary completion | Oct 1, 2004 |
| Completion | Oct 1, 2004 |
| First posted | Aug 24, 2006 |
| Last update posted | Feb 22, 2012 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: